Basal cell carcinoma - Carcinoma Cealla Basal
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Thathas gu tric a’ faighinn a-mach gu bheil leòintean ulcerated a bheir buaidh air craiceann an t-sròin ann an seann neach mar Carcinoma Cealla Basal (Basal cell carcinoma). Tha an t-sròin na làrach cumanta airson an seòrsa seo de aillse craiceann.
Dh’ fhaodadh Carcinoma Cealla Basal (Basal cell carcinoma) nochdadh le crìochan neo-riaghailteach agus ulcers.
Faodar mearachd a dhèanamh air Carcinoma Cealla Basal (Basal cell carcinoma) airson wart.
References
Is e Basal cell carcinoma (BCC) an seòrsa aillse craiceann as cumanta. Is e foillseachadh solas na grèine am prìomh adhbhar. Tha cha mhòr a h-uile cùis BCC a’ nochdadh comharran gràineag cus-ghnìomhach anns an anailis moileciuil. Tha diofar leigheasan rim faighinn agus air an taghadh a rèir cunnart ath-chuairteachaidh, cudromachd gleidheadh fighe, roghainn euslaintich, agus ìre galair.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas an seòrsa aillse craiceann as cumanta ann an inbhich le craiceann cothromach aois 50 agus nas sine. Tha na h-àireamhan aca ag èirigh air feadh an t-saoghail, gu h-àraidh mar thoradh air a bhith fosgailte do sholas na grèine. Faodaidh cuid de shuidheachaidhean ginteil toirt air daoine a bhith buailteach na cansean sin a leasachadh aig aois nas òige. Basal cell carcinomas eadar-dhealaichte ann an doimhneachd, bho leòintean uachdarach no nodular a tha furasta an làimhseachadh gu feadhainn nas fharsainge a dh’ fheumas deasbad ann an sgiobaidhean meidigeach sònraichte. Tha an prognosis an urra ris a’ choltas gun till aillse no a chomas milleadh a dhèanamh air maothran faisg air làimh. Is e lannsaireachd an làimhseachadh àbhaisteach airson a’ mhòr-chuid de chùisean, a’ dèanamh cinnteach à toirt air falbh mionaideach agus cothroman ìosal gun till iad a-rithist. Faodaidh dòighean nach eil cho ionnsaigheach dèiligeadh gu h-èifeachdach ri lotan uachdar.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Is e lannsaireachd am prìomh làimhseachadh airson BCC. Airson BCC àrd-chunnart no ath-chuairteachaidh, gu sònraichte ann an raointean èiginneach, thathas a’ moladh lannsaireachd fo smachd micrografach. Dh’ fhaodadh euslaintich le BCC le cunnart ìosal beachdachadh air làimhseachadh gnàthach no dòighean millteach. Tha leigheas photodynamic ag obair gu math airson BCC nodular uachdarach agus le cunnart ìosal. Airson BCC adhartach gu h-ionadail no meatastatach, thathas a’ moladh luchd-dìon gràineag (vismodegib, sonidegib) . Ma tha adhartas galair ann no neo-fhulangas ri luchd-bacadh gràineag, faodar beachdachadh air immunotherapy le anti-PD1 antibody (cemiplimab) . Tha radiotherapy na dheagh roghainn dha euslaintich nach urrainn obair-lannsa fhaighinn, gu sònraichte euslaintich nas sine. Faodar beachdachadh air electrochemotherapy mura h-eil lannsaireachd no radiotherapy na roghainn.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Tha factaran cunnairt a’ toirt a-steach a bhith fosgailte do sholas ultraviolet, leigheas rèididheachd, eòlas fad-ùine air arsenic agus droch ghnìomhachd siostam dìon (me tar-chuir organan). Tha a bhith fosgailte do sholas UV rè leanabachd gu sònraichte cronail.
Às deidh breithneachadh le biopsy, mar as trice bidh làimhseachadh le toirt air falbh lannsaireachd. Faodaidh seo a bhith air a ghearradh gu sìmplidh ma tha an aillse beag; Mura h-eil an aillse beag, mar as trice thathar a 'moladh lannsaireachd Mohs.
Tha carcinoma cealla basal a’ dèanamh suas co-dhiù 32% de gach aillse air feadh na cruinne. A-mach à cansearan craiceann a bharrachd air melanoma, tha timcheall air 80% nan cansearan cealla basal. Anns na Stàitean Aonaichte, tha carcinoma cealla basal a’ toirt buaidh air timcheall air 35% de fhireannaich gheala agus 25% de bhoireannaich gheal aig àm air choreigin nam beatha.
○ Diagnosis agus Làimhseachadh
#Dermoscopy
#Skin biopsy
#Mohs surgery